Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y ibritumomab tiuxetan radioimmunotherapy in CD20-positive indolent B-cell non-Hodgkin lymphoma
ISRCTN36210045Phase 4Completed
- Sponsor
- Foundation for the Study of Hematology in Aragon
- Start
- Sep 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ibritumomab tiuxetan and rituximab in mature B-cell lymphoma and follicular lymphoma (FL), sponsored by Foundation for the Study of Hematology in Aragon. Primary endpoint: Response assessment at 12 weeks. Started Sep 2005; status: completed.
02
Drugs
ibritumomab tiuxetanrituximab
03
Conditions
mature B-cell lymphomafollicular lymphoma (FL)
Beyond the preview
Go deeper on ISRCTN36210045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN36210045.